Latest Breaking News On - Marina basina - Page 1 : comparemela.com
Medical Affairs Team
medicalnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalnewstoday.com Daily Mail and Mail on Sunday newspapers.
Medical Affairs Team
psychcentral.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychcentral.com Daily Mail and Mail on Sunday newspapers.
Medical Affairs Team
healthline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthline.com Daily Mail and Mail on Sunday newspapers.
and Corresponding Risk Reduction Over Time NEW YORK, June 28, 2021 - Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and improvements in kidney health over time in adults with type 2 diabetes. By accurately assessing therapeutic response, particularly in patients at high risk for kidney failure, KidneyIntelX can potentially address a major barrier for primary care physicians and specialists in using new pharmaceuticals to slow kidney disease and improve outcomes. The data from an international study of 1,100 individuals with diabetic kidney disease (DKD) in the CANagliflozin Cardiovascular Assessment Study (CANVAS), was presented at the American Diabetes Association 81st Scientific Sessions Virtual Meeting (June 25-29, 2021).
Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes
April 05, 2021 07:00 ET | Source: Renalytix AI plc. Renalytix AI plc. New York, New York, UNITED STATES
NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care. The results of the study, which is the second peer-reviewed clinical validation study on KidneyIntelX, have been published in